1
SAVE THE DATE The Division of Blood Disorders (DBD) is proud to launch its “Webinar Series on Bleeding and Clotting Disorders.” This new webinar series will provide evidence-based information on new research, interventions, emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships. We invite you to join us for the first topic in this series. To join the webinar, visit: https://www.livemeeting.com/cc/cdc/join?id=B2PW88&role=attend Enter the meeting ID: B2PW88 and click “join” To hear the presentation, call the toll-free number, dial 1-866-692-4541 and enter the participant code: 13565573 TOPIC Venous Thromboembolism and Cancer GUEST Alok A. Khorana, MD PRESENTER Sondra and Stephen Hardis Chair in Oncology Research and Director of the Gastrointestinal Malignancies Program at Taussig Cancer Institute of the Cleveland Clinic WHEN OCTOBER 10, 2013 2:00–3:00 pm EST WEBINAR Venous thromboembolism (VTE) is highly prevalent in people undergoing DESCRIPTION treatment for cancer. Serious consequences for cancer patients include the need for hospitalization, long-term anticoagulation, and death. Recent large clinical trials have addressed thromboprophylaxis in the outpatient setting with potential benefit of reducing morbidity and mortality. However, these studies also show considerable variation in underlying risk. In this webinar, Dr. Khorana will discuss the importance of VTE risk assessment for guiding outpatient prevention practices. LEARNING Understand the burden of VTE and cancer OBJECTIVES Identify current strategies for risk assessment Learn about a validated risk score for VTE and cancer Apply risk assessment tools WHO SHOULD This webinar is free and open to all who are interested in learning about ATTEND cancer-associated VTE, its prevention, treatment and management. The number of phone lines is limited. For more information about the webinar, please contact Cynthia Sayers at [email protected] or 404-498-0020. National Center on Birth Defects and Developmental Disabilities Division of Blood Disorders

OCTOBER 10, 2013 · at Taussig Cancer Institute of the Cleveland Clinic. WHEN. OCTOBER 10, 2013. 2:00–3:00. pm EST. WEBINAR . Venous thromboembolism (VTE) is highly prevalent in

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: OCTOBER 10, 2013 · at Taussig Cancer Institute of the Cleveland Clinic. WHEN. OCTOBER 10, 2013. 2:00–3:00. pm EST. WEBINAR . Venous thromboembolism (VTE) is highly prevalent in

SAVE THE

DATEThe Division of Blood Disorders (DBD) is proud to launch its “Webinar Series on Bleeding and Clotting Disorders.” This new webinar series will provide evidence-based information on new research, interventions, emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships. We invite you to join us for the first topic in this series.

To join the webinar, visit: https://www.livemeeting.com/cc/cdc/join?id=B2PW88&role=attendEnter the meeting ID: B2PW88 and click “join”To hear the presentation, call the toll-free number, dial 1-866-692-4541 and enter the participant code: 13565573

TOPIC Venous Thromboembolism and Cancer

GUEST Alok A. Khorana, MD PRESENTER Sondra and Stephen Hardis Chair in Oncology Research

and Director of the Gastrointestinal Malignancies Program at Taussig Cancer Institute of the Cleveland Clinic

WHEN OCTOBER 10, 2013 2:00–3:00pm EST

WEBINAR Venous thromboembolism (VTE) is highly prevalent in people undergoing DESCRIPTION treatment for cancer. Serious consequences for cancer patients include the

need for hospitalization, long-term anticoagulation, and death. Recent large clinical trials have addressed thromboprophylaxis in the outpatient setting with potential benefit of reducing morbidity and mortality. However, these studies also show considerable variation in underlying risk. In this webinar, Dr. Khorana will discuss the importance of VTE risk assessment for guiding outpatient prevention practices.

LEARNING ▶ Understand the burden of VTE and cancer OBJECTIVES ▶ Identify current strategies for risk assessment ▶ Learn about a validated risk score for VTE and cancer ▶ Apply risk assessment tools

WHO SHOULD This webinar is free and open to all who are interested in learning about ATTEND cancer-associated VTE, its prevention, treatment and management. The number

of phone lines is limited.

For more information about the webinar, please contact Cynthia Sayers at [email protected] or 404-498-0020.

National Center on Birth Defects and Developmental DisabilitiesDivision of Blood Disorders